Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha9/15/2026Neutral
ALEC
Alector IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$217.73M
P/E Ratio
—
EPS
$-1.03
Beta
0.65
52W High
$3.40
52W Low
$1.09
50-Day MA
$1.97
200-Day MA
$1.98
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
8.47
PEG Ratio
—
About Alector Inc
Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $13.86M |
| Gross Profit (TTM) | $-85.27M |
| EBITDA | $-119.03M |
| Operating Margin | -735.00% |
| Return on Equity | -385.10% |
| Return on Assets | -27.60% |
| Revenue/Share (TTM) | $0.13 |
| Book Value | $-0.09 |
| Price-to-Book | 19.57 |
| Price-to-Sales (TTM) | 15.71 |
| EV/Revenue | 6.01 |
| EV/EBITDA | -8.40 |
| Quarterly Earnings Growth (YoY) | -86.30% |
| Quarterly Revenue Growth (YoY) | -57.80% |
| Shares Outstanding | $111.66M |
| Float | $89.41M |
| % Insiders | 9.52% |
| % Institutions | 93.29% |
Historical Volatility
HV 10-Day
69.53%
HV 20-Day
85.00%
HV 30-Day
86.33%
HV 60-Day
100.67%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($3.10 target)
3
Buy3
Hold1
Sell1
Strong SellLatest News
Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript
Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript
Seeking Alpha9/15/2026Neutral
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 (New York, New York) Thursday, September 10, 2026, at 2:10 p.m.
GlobeNewsWire9/3/2026Neutral
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer's disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies)
GlobeNewsWire5/7/2026Neutral
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research5/7/2026Negative
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis
--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer's disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson's disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and metabolic disorders, alongside several first-in-class discovery programs— SOUTH SAN FRANCISCO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today confirmed that the Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) in individuals with early Alzheimer's disease (AD) will be discontinued.
GlobeNewsWire4/29/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALEC and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026